FARMINGDALE, N.Y., Nov. 7, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announced today that it will exhibit and host several educational panels led by top spine surgeons at the North American Spine Society ("NASS") annual meeting in San Francisco, CA taking place November 12 - 14, 2014.NASS is a global, multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value- and evidence-based spine care for patients1.
"Misonix is proud to be a part of this year's NASS meeting," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We will be demonstrating the BoneScalpel to confirm to surgeons the value ultrasonic technology can add to spine surgery."
At its tradeshow booth (#510), the Misonix team will be featuring the BoneScalpel system, an ultrasonic device that features a precise bone cutting instrument that enables surgeons to make clean, controlled bone incisions and removal, and that also spares soft tissue.
To detail the benefits of the BoneScalpel in spine surgery, Misonix will be hosting several "Meet the Expert" sessions, which will be moderated by several top spine surgeons:
- Dr. Nicholas Renaldo, Vassar Brothers Medical Center, Poughkeepsie, NY
- Dr. Justin Bird, Houston, TX
- Dr. Connor Telles, Sierra Pacific Orthopedics, Fresno, CA
- Dr. Harvey Smith, University of Pennsylvania, Philadelphia, PA
- Dr. Greg Mundis, Scripps Clinic Orthopedic Surgery, San Diego, CA
Dr. Mundis explained, "During the 'Meet the Expert' sessions, spine surgeons will learn several applications of the BoneScalpel in spine surgery along with the benefits this unique technology offers both surgeons and patients. In my practice, the BoneScalpel provides for improved surgical efficiencies, reduced bleeding and soft tissue protection while offering controlled incising of bone and hard tissue during spinal procedures."
The Company expects all five "Meet the Expert" sessions to be well attended and generate healthy discussions on applying the BoneScalpel in various spinal procedures.
The Bone Scalpel will also be featured at the NASS Solutions Showcase (Booth #2504) on Thursday, November 13th at 12:30 pm. This showcase will contain the following presentations:
- Principles of ultrasonic bone dissection and clinical experience by Dr. Isador Lieberman, MD, Texas Back Institute, Texas Health Plano Hospital, Plano, TX.
- Our experience in adopting the ultrasonic BoneScalpel in our spine program by Dr. Shane Burch, MD, University of California Medical Center, San Francisco, CA.
Mr. McManus concluded, "The NASS meeting is a fantastic opportunity for Misonix to spotlight the BoneScalpel, instruct surgeons on the value of our technology and demonstrate the use of the BoneScalpel in a variety of procedures. We look forward to a very successful event."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.